The European Medicines Agency (EMA) on Friday gave the green light to injection therapy for HIV, a first that could change the lives of millions of people living with AIDS or living with HIV.
• Read also: The first man cured of HIV died of cancer
The cocktail of two antiretrovirals (ARVs) can be injected monthly or every two months, replacing a daily dose of pills to contain the HIV infection, the agency said in a statement, stressing that these two ARVs were the “first “To have a” long-lasting “action, in the form of an injection.
“This means that instead of daily pills, patients are given intramuscular injections every month or two,” the statement said.
The recommendation for marketing authorization for this therapy must now be approved by the European Commission before it is placed on the market in the 27 Member States of the Union.
This new therapy could change the lives of people infected with HIV, especially those who forget to take their daily treatment, which increases the risk of the virus developing.
The new ARV, a cocktail of rilpivirine and cabotegravir – marketed under the names Rekambys and Vocabria – helps “block the ability of the virus to replicate”, according to the Agency.
Some 38 million people were living with HIV worldwide in 2019, including 2.3 million in Europe, according to the World Health Organization (WHO).
There is no treatment for the disease, although ARVs can control the virus and help prevent its transmission.